DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the AVIENCE BIOMEDICALS LTD (AVIENCE) share price today?

AVIENCE BIOMEDICALS LTD (AVIENCE) is trading at ₹222.85 on the NSE, down 19.69% on the day. Source: DocStoX.

What is the PE ratio of AVIENCE BIOMEDICALS LTD?

AVIENCE BIOMEDICALS LTD has a price-to-earnings (PE) ratio of 15.7 in the Healthcare sector.

What is the market capitalisation of AVIENCE BIOMEDICALS LTD?

AVIENCE BIOMEDICALS LTD has a market capitalisation of approximately ₹155 crore.

AVIENCE BIOMEDICALS LTD

AVIENCE·NSE·Healthcare

₹222.85▼ -54.65 (-19.69%)

Healthcare · Medical Equipment & Supplies

High-quality returns — 25% on equity

Day₹222.00

₹272.00

52W₹222

₹4150%

Open

₹271.00

High

₹272.00

Low

₹222.00

Prev Close

₹277.50

Volume

5.67L

VWAP

₹231.42

Snapshot

Key fundamentals

Market Cap

₹155 Cr

P/E Ratio

15.65Fair

P/B Ratio

1.82

EPS

₹14.24

Book Value

₹159.61

ROE

25.30%Strong

ROCE

21.10%Efficient

Dividend Yield

0.00%

Debt / Equity

1.29Elevated

Face Value

₹10.00

52W High

₹414.95

52W Low

₹222.00

Sector

Healthcare

Industry

Medical Equipment & Supplies

Fairly Valued

Narrow moatMedium uncertainty

Fair value estimate

₹251

▲ 12.7%upside

Trading at ₹223 — 13% below our estimate

BearFair valueBull

₹213₹251₹289

/100

Business quality — Solid

Growth 50Profitability 83Efficiency 33Valuation 61

Plain English

Our view

High-quality returns — 25% on equity
Strong returns on equity (25%)
Fundamental red flags (Piotroski 1/9)

Strengths

Strong returns on equity (25%)
Capital is working hard (ROCE 21%)
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

25% ROE fading to 14% over ~10 yrs, on ₹160 book

₹258

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹226

Analyst target

No analyst coverage

—

Blended fair value₹251

What the numbers say

Investment thesis

Bull case

Strong returns on equity (25%)
Capital is working hard (ROCE 21%)
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

15.7Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

25.3%Strong

Above 15% is considered healthy for Indian equities

ROCE

21.1%Efficient

Above 18% means capital is working hard

Debt/Eq

1.29Elevated

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹155 Cr

P/B

1.82

EPS

₹14.24

Div Yield

—

What changed

Recent changes

Foreign investors+3.1% stake last quarter
Domestic institutions+9.1% stake last quarter
Promoters-28.26% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 15.7×

Growth

N/A

No history

Profitability

Excellent

25.3% ROE

Financial health

Leveraged

D/E 1.29

Momentum

N/A

No technicals

Today

Trading activity

Delivery %54.6%

Turnover₹1312.13L Cr

Trades586

VWAP₹231.42

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 34.8%

Watch-outs

Cons

Company might be capitalizing the interest cost
Company has high debtors of 150 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters trimmed their stake by 28.26 pts; foreign investors bought 3.06 pts; domestic institutions added 9.08 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

65%

Promoter

Promoters

64.6%-28.26

Public

23.3%+23.26

FII / FPI

3.1%+3.06

DII

9.1%+9.08

Total shareholders

38+1 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter64.59%

FII3.06%

DII9.08%

Public23.26%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions.[1]